Why Intuitive Surgical (ISRG) Is Drawing Attention Now

Intuitive Surgical (ISRG) is back on many watchlists after a stretch of weaker share performance, with the stock down about 8% over the past month and 13% over the past 3 months.

At a share price of US$421.12, Intuitive Surgical has seen shorter term momentum fade, with the share price return down over the past week and month, even though the 5 year total shareholder return remains positive.

If you are watching how surgical robotics resets expectations, it can be useful to see what else is moving in related areas through the 32 healthcare AI stocks.

With Intuitive Surgical stock down over the past year, but the company still reporting double digit revenue and net income growth, the key question is whether recent weakness signals a potential opening or whether the market is already pricing in future growth.

Most Popular Narrative: 20.9% Undervalued

According to the most followed narrative on Intuitive Surgical, the fair value of $532.46 sits well above the last close at $421.12, which frames the recent share price weakness in a very different light.

Over the next 5 years I calculate with (actual values from 18.01.26, price/shr at 533 USD): Revenue Growth p.a.: 12% (Currently at 14.7%). We saw the peak of revenue growth with nearly 15%, now even 12% is sporty, but with the “abo like” revenues from spare parts and software licences, based on a still growing bases of installed systems, realistic. Profit Margin: 30% (currently at 28.6%) because spare parts in general have more margin than system sales, and the sales out of spare parts is still growing. Future PE: 50 (currently at 69). The high PEs are typical for fast growers, but over time the PE will go down, I see for next 5 years 50, in 10 years it could come down to 40. Interest rate: 6.77% (same as current). Which leads to an FV of 533 USD, means ISRG trades with 0.5% at fair value.

Want to see how recurring procedure volumes, richer margins and a reset in valuation multiples all tie together into that fair value estimate? The narrative by Tokyo connects revenue growth, profitability and the future P/E assumption into one tight model, but the balance between growth expectations and required return is not obvious at a glance.

Result: Fair Value of $532.46 (UNDERVALUED)

However, this narrative could be challenged if procedure volumes slow or if competitors in surgical robotics begin to pressure pricing and hospital budgets.

Another Angle On Value: High P/E, Different Story

The popular narrative points to a fair value of $532.46 and an undervalued stock, but the market snapshot looks less forgiving. Intuitive Surgical trades on a P/E of 50.1x, compared with an estimated fair ratio of 32x, the Medical Equipment industry at 25.2x and peers at 25.5x.

That gap suggests you could be paying a premium today for growth that others see as more modest. The real question is whether you are comfortable underwriting that kind of valuation risk if sentiment cools again.

Next Steps

If the mixed messages on price and growth have you uncertain, consider acting while sentiment is still shifting and weigh the potential upside yourself by checking the 3 key rewards

Looking for more investment ideas?

If Intuitive Surgical has sharpened your thinking about quality and price, do not stop here. Broaden your watchlist with focused stock ideas built from hard numbers.

• Target resilient cash generators and test your patience for value by scanning 50 high quality undervalued stocks that pair quality fundamentals with discounted prices.
• Strengthen your income stream by examining 12 dividend fortresses where yield and stability work together instead of pulling in opposite directions.
• Stay early to potential standouts by tracking the screener containing 22 high quality undiscovered gems before they sit on everyone else’s radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.